Market Overview

Morning Market Losers

Related MODN
Benzinga's Volume Movers
Events for the Week of Aug. 25-29th
Related NBIX
Events for the Week of Nov. 17-21, 2014
Neurocrine Initiates Tourette Syndrome Clinical Trial

Model N (NYSE: MODN) dropped 31.57% to $10.08 on downbeat FY14 forecast. JP Morgan downgraded the stock from “overweight” to “neutral.”

Neurocrine Biosciences (NASDAQ: NBIX) plummeted 29.82% to $11.72 after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia.

ChemoCentryx (NASDAQ: CCXI) dropped 23.97% to $6.28 after the company announced top-line interim results for CCX140 in an ongoing Phase II trial.

HD Supply Holdings (NASDAQ: HDS) dropped 11.59% to $21.88 on Q2 results.

Posted-In: Morning Market LosersNews Movers & Shakers Intraday Update Markets

 

Related Articles (CCXI + HDS)

Around the Web, We're Loving...

Get Benzinga's Newsletters